Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448916 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
A Phase 3 study of Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
- 18
- Study locations
NCT00448916 is a Phase 3 study of Epilepsies, Partial that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 54 participants, roughly in line with the 59-participant average among 4 other Epilepsies, Partial trials with a reported enrollment target. The trial reports 18 study locations across 11 states.
The verdict
NCT00448916, a Phase 3 study of Epilepsies, Partial, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
- 18
- Study locations
Study Summary
The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.
Conditions Studied
Interventions
- DRUG Pregabalin
Study Locations (18)
Florida
- Child Neurology Center of Northwest Florida - Gulf Breeze
- The Office of Sergio J Jacinto, MD - Tampa
- Pediatric Epilepsy & Neurology Specialists - Tampa
Texas
- Baylor College of Medicine - Texas Children's Hospital - Houston
- Texas Children's Hospital - Houston
- Road Runner Research, Ltd. - San Antonio
Alabama
- University of South Alabama - Mobile
- University of South Alabama Department of Neurology - Mobile
Arkansas
- The Children's Clinica of Jonesboro, P.A - Jonesboro
- Clinical Study Centers, L. L. C. - Little Rock
Missouri
- St. John's Clinic - Springfield
- St. John's Hospital - Springfield
Arizona
- Phoenix Children's Hospital - Phoenix
California
- UCSF Neurology Clinic - San Francisco
New York
- Women and Children's Hospital of Buffalo - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2007-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00448916
The ClinicalTrials.gov registry entry for NCT00448916 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 59-participant average among 4 other Epilepsies, Partial trials with a reported enrollment target. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsies, Partial appearing as the primary indexed condition, and to 1 intervention - of which Pregabalin is the first listed.
NCT00448916 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Florida, Texas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00448916 about?
NCT00448916 is a clinical study titled "Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures". The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.
What is the current status of trial NCT00448916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2007-05. Estimated completion is 2013-10.
What conditions does trial NCT00448916 study?
This clinical trial studies the following conditions: Epilepsies, Partial.
What interventions are being tested in trial NCT00448916?
The interventions under investigation include: Pregabalin (DRUG).
Who is sponsoring clinical trial NCT00448916?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00448916 being conducted?
This trial has 18 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsies, Partial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
-
Transcranial Direct Current to Treat Epilepsy at Home
ACTIVE NOT RECRUITING · NA
-
Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study
COMPLETED · NA
-
Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.